Immunomedics (IMMU) keeps falling due to poor news
Immunomedics, Inc. (IMMU) currently trades at $10.28 and has fallen by 23.81% today. It has been about a month since the last earnings report for Immunomedics (IMMU). Shares have lost about 18% in that time frame, underperforming the S&P 500. Immunomedics incurred a loss of 50 cents per share in fourth-quarter 2019, wider than expected by analysts of a loss of 45 cents but in line with the loss incurred in the year-ago quarter. Total revenues were $0.3 million in the quarter, including service fee revenues earned related to the Janssen Promotion agreement.
Based on this information, investorsQ rates this stock 3 out of 10. We give it this rating because Total costs and expenses were $91.5 million in the fourth quarter compared with $87.4 million a year ago, mainly due to increase in research & development expenses mostly attributable to activities related to preparations for the approval and commercial launch of sacituzumab govitecan for patients with at least two prior lines of treatment for metastatic triple-negative breast cancer(mTNBC) in the United States — as well as CRL remediation costs. The high forecast for Immunomedics, Inc. is $35.00 and the low is $16.00. Notably, the company’s market cap is $2.24 billion with a 52 week high of $22.22 and a 52 week low of $9.18.